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Malignant mesothelioma (MM) is a fatal type of neoplasia with poor therapeutic prognosis, largely due to resistance to apoptosis. We
investigated the apoptotic effect of a-tocopheryl succinate (a-TOS), a strong proapoptotic agent, in combination with the
immunological apoptogen TNF-related apoptosis-inducing ligand (TRAIL) on both MM and nonmalignant mesothelial cells, since MM
cells show low susceptibility to the clinically intriguing TRAIL. All MM cell lines tested were sensitive to a-TOS-induced apoptosis, and
exerted high sensitivity to TRAIL in the presence of subapoptotic doses of the vitamin E analogue. Neither TRAIL or a-TOS alone or
in combination caused apoptosis in nonmalignant mesothelial cells. Isobologram analysis of the cytotoxicity assays revealed a
synergistic interaction between the two agents in MM cells and their antagonistic effect in nonmalignant mesothelial cells. TRAIL-
induced apoptosis and its augmentation by a-TOS were inhibited by the caspase-8 inhibitor Z-IETD-FMK and the pan-caspase
inhibitor Z-VAD-FMK. Activation of caspase-8 was required to induce apoptosis, which was amplified by a-TOS via cytochrome c
release following Bid cleavage, with ensuing activation of caspase-9. Enhancement of TRAIL-induced apoptosis in MM cells by a-TOS
was also associated with upregulation of the TRAIL cognate death receptors DR4 and DR5. Our results show that a-TOS and TRAIL
act in synergism to kill MM cells via mitochondrial pathway, and are nontoxic to nonmalignant mesothelial cells. These findings are
indicative of a novel strategy for treatment of thus far fatal MM.
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Human malignant mesothelioma (MM) represents a tumour,
which arises from mesothelial cells of the pleura or peritoneal
cavities. The pathogenesis of this disease is associated with
exposure to asbestos fibres (Mossman et al, 1996). Recently,
Simian virus-40 (SV-40) has been associated with this malignancy
(Carbone et al, 1994). The SV-40 oncogenic proteins bind and
inactivate cellular p53 (Carbone et al, 1997) and the SV-40-positive
status negatively affects the prognostic outcome of MM patients
(Procopio et al, 2000). A typical feature of MM is its resistance to
both chemotherapeutic agents and radiation (Houghton, 1999;
Tomek et al, 2003). The general resistance of MM cells to apoptosis
may explain the insensitivity of mesothelioma to therapy
(Narasimhan et al, 1998), which has been shown for a variety of
apoptotic agonists, although its mechanism has not been
elucidated (Soini et al, 1999).
The immunological proapoptotic agent, tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL, Apo2L) induces apop-
tosis in a wide variety of malignant cells without exhibiting
systemic toxicity to normal cells or tissues (French and Tschopp,
1999). The mechanism of TRAIL proapoptotic signalling includes
its interaction with two death domain-containing receptors, DR4
(TRAIL-R1) and DR5 (TRAIL-R2). Although DR4 and DR5 are
both widely expressed in human tissue, normal cells are usually
resistant to TRAIL (Ashkenazi and Dixit, 1998). The reason may be
that normal cells often express TRAIL decoy receptors (DcRs),
DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4), which compete with the
death receptors (DRs) (Ashkenazi and Dixit, 1999). Based on the
observations of an increase in DR5 expression by DNA-damaging
agents that induce apoptosis in a p53-dependent manner (Wu et al,
1997), it has been suggested that TRAIL-dependent signalling may
be related to p53 activation (Sheikh et al, 1998). Thus, agents
capable of upregulating expression of TRAIL DRs are likely to
enhance susceptibility of cells to TRAIL. Indeed, chemotherapeutic
compounds like doxorubicine, 5-fluorouracil, and CPT-11 showed
a synergy in apoptosis induction with TRAIL, and suppressed
tumour growth in animal models (Gliniak and Le, 1999; Keane et al,
1999). These findings are consistent with the notion that cancer
can be treated more efficiently by combination of agents with
synergistic/additive activities.
Several groups have shown that a semisynthetic analogue of
vitamin E, a-tocopheryl succinate (a-TOS), is a potent inducer of
apoptosis in a variety of malignant cells (Yu et al, 1999; Yamamoto
et al, 2000; Neuzil et al, 2001a), while being largely nontoxic to
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snormal cells and tissues (Neuzil et al, 2001a; Weber et al, 2002).
The apoptotic effect of a-TOS involves lysosomal and mitochon-
drial destabilisation as well as caspase-3 activation (Alleva et al,
2001; Neuzil et al, 2001b). a-Tocopheryl succinate-induced
apoptosis may be amplified by protein kinase C (PKC) inhibition
(Neuzil et al, 2001b). Recently, a-TOS has been shown to exert
antineoplastic activity and to promote tumour dormancy in
preclinical models (Malafa and Neitzel, 2000; Weber et al, 2002).
Finally, a-TOS has been reported to sensitise resistant breast
cancer cells to Fas killing (Yu et al, 1999) as well as to cooperate
with TRAIL in apoptosis induction in colon cancer cells and in
colon carcinoma growth suppression (Weber et al, 2002).
Here we have investigated the effect of a-TOS and TRAIL in MM
cells to test their potential ability to cooperatively induce
apoptosis. We show that MM cells are highly susceptible to a-
TOS, which synergises with TRAIL. Neither a-TOS nor TRAIL
alone or in combination showed toxicity to nonmalignant
mesothelial cells; rather, the a-TOS antagonised the nonmalignant
cells to the effects of TRAIL. These findings support the emerging
idea of the vitamin E analogue as a novel anticancer agent and/or
adjuvant (Neuzil, 2002).
MATERIALS AND METHODS
Reagents
a-Tocopheryl succinate, annexin V-FITC, low melting point
agarose, agarose, (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT), and 40,6-diamino-2-phenylindole (DAPI)
were purchased from Sigma (St Louis, MO, USA). Soluble human
recombinant tumour necrosis factor-related apoptosis-inducing
ligand (hrTRAIL) was prepared as described elsewhere (Plasilova
et al, 2002). Anti-DR4, anti-DR5, and anti-DcR1 monoclonal IgG
were obtained from Alexis Biochemicals (Lausen, Switzerland),
and the anti-DcR2 polyclonal IgG from ProSci (Poway, CA, USA),
anticytochrome c and anti-Bid IgG were from Pharmigen (San
Diego, CA, USA), anticaspase-8 monoclonal IgG from Upstate
Biotechnology (Lake Placid, NY, USA), and anticaspase-9 poly-
clonal IgG from Santa Cruz (Santa Cruz, CA, USA). All primers for
RT–PCR were obtained from Sigma Genosys (St Louis, MO, USA).
The colorimetric substrates for caspase-8 (Ac-IETD-pNA) and
caspase-9 (Ac-LEHD-pNA), the caspase-8 inhibitor (Z-IETD-
FMK), and the pan-caspase inhibitor (Z-VAD-FMK) were pur-
chased from Calbiochem (San Diego, CA, USA). Foetal Bovine
Serum (FBS) was obtained from EuroClone (Paignton, UK). The
plasmids harbouring the green fluorescent protein (GFP) and the
red fluorescence protein (RFP), pGFP, and pDsRed1-N1, respec-
tively, were obtained from BD Biosciences (Palo Alto, CA, USA).
Cell culture
The MM-B1 (biphasic), Meso-2 (sarcomatoid), and Ist-Mes
(epithelioid) human MM cell lines were used (Pass et al, 1995).
The nonmalignant mesothelial cell line, Met-5A (ATTC, Rockville,
MD, USA), was used as a nonmalignant control. HeLa cells
were obtained from ATCC and used as a positive control for the
expression of TRAIL receptors. The cells were cultured in the
RPMI-1640 medium supplemented with 2mML -glutamine,
100Uml
 1 penicillin, 100mgml
 1 streptomycin, and 10% FBS.
Cytotoxicity and isobologram analysis
MM cells were plated in 96-well flat-bottom tissue culture plate at
2.5 10
3 per well. The cells were allowed to attach overnight, and
then incubated for 24h with a-TOS and hrTRAIL at p100mM and
p10mgml
 1, respectively. a-Tocopheryl succinate was dissolved
in ethanol and diluted in complete RPMI-1640 to the final
concentration, and was added to cells at 0.1% (vv
 1) of ethanol.
Cell viability were determined using MTT (Carmichael et al, 1987).
Briefly, following exposure of cells, 10ml of MTT (5mgml
 1 in
PBS) was added, and after incubation for 4h at 371C, the medium
was removed and combined with 200ml of 1% SDS. Absorbance
was read at 550nm using an ELISA plate reader and control
absorbance was designed as 100%, with percentage of it as a cell
survival. Survival curves were generated for a-TOS and hrTRAIL,
and the IC50 values were determined. The effect of combination of
the drugs on MM and nonmalignant mesothelial cells was
estimated by using the isobologram evaluation (Tsai et al, 1989).
Briefly, the cells were incubated with both agents added
simultaneously to the cell culture medium at different concentra-
tions, and the IC50 values for each drug in combination were
calculated. Isobolograms were plotted at the individual IC50 values.
Apoptosis detection
Annexin V-FITC assay Apoptosis was quantified using the
annexin V-FITC method, which detects phosphatidyl serine (PS)
externalised in the early phases of apoptosis (Boersma et al, 1996).
Briefly, cells were plated at 10
5 per well in 24-well plates. After an
overnight incubation, cells were treated with a-TOS (30mM)o r
hrTRAIL (50ngml
 1) alone or in combination. Floating and
attached cells were collected, washed twice with PBS, resuspended
in 0.1ml binding buffer (10mM HEPES, 140mM NaCl, 5mM CaCl2,
pH 7.4), incubated for 20min at room temperature with 2ml
annexin V-FITC, supplemented with 10ml of propidium iodide (PI)
(10mgml
 1), and analysed by flow cytometry (Becton Dickinson,
Rutherford, NJ, USA), using channel 1 for annexin V-FITC binding
and channel 2 for PI staining.
Comet assay DNA fragmentation was analysed using the neutral
comet assay (Kizilian et al, 1999). Cells were sandwiched between
thin layers of agarose on a microscope slide, lysed at neutral pH,
electrophoresed, and stained with a silver dye. During electro-
phoresis, loops or pieces of DNA migrate away from the nuclear
remnant to produce a shape with the visual characteristics of a
comet. The comet assay can thus distinguish apoptotic from
nonapoptotic cells on the basis of their characteristic DNA
fragmentation pattern (Tomasetti et al, 2001).
Western blotting
Cells were treated as indicated and lysed in a buffer containing 1%
Nonidet, 5mM DTT, 150mM NaCl, 2mM EDTA, 50mM Tris-HCl,
pH 7.4, and a cocktail of protease inhibitors, and stored at  801C
until analysis. Cell extracts were mixed with the sample buffer
containing 12mM Tris-HCl, pH 6.8, 6% SDS, 10% b-mercaptoetha-
nol, 20% glycerol, and 0.03% bromophenol blue. Protein samples
(100mg per lane) were boiled for 5min and electrophoresed in
12.5% polyacrylamide gels. Separated proteins were transferred
onto a nylon membrane and blocked with 5% skimmed milk in
PBS containing 0.1% Tween-20 (PBS-T) for 1h at room
temperature. Immunodetection was performed overnight at 41C
in PBS-T using anticaspase-8, anticaspase-9 and anti-Bid IgG. After
incubation with an HRP-conjugated secondary IgG (Amersham,
London, UK), the blots were developed using ECL (Pierce,
Rockford, IL, USA). Protein loading was corrected for b-actin.
Caspase activity assay
After a-TOS (30mM) and/or hrTRAIL (50ngml
 1) treatment, cells
were harvested at different time points and lysed in the caspase
lysis buffer (1% Nonidet, 5mM DTT, 150mM NaCl, 2mM EDTA,
50mM Tris-HCl, pH 7.4) containing a cocktail of protease
inhibitors. The cytosolic fraction (10mg protein) was incubated
at 371C in the caspase reaction buffer (1% Nonidet, 100mM NaCl,
10mM DTT, 0.1mM EDTA, 50mM HEPES, pH 7.5, and 10%
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sglycerol), containing the specific colorimetric substrates for
caspases, Ac-IETD-pNA for caspase-8 or Ac-LEHD-pNA for
caspase-9, in a total volume of 100ml. Caspase activity was
evaluated as cleavage of the substrate and monitored at 405nm in
an ELISA plate reader. Caspase activity rates were expressed as
optical density (OD) per min, and normalised for protein.
TRAIL receptor analysis
Expression of TRAIL receptors (DR4, DR5, DcR1, DcR2) was
evaluated by flow cytometry before and after treatment with a-TOS
(30mM). MM and Met-5A cells were seeded 24h before the
treatment in six-well plates at 3 10
5 per well. HeLa cells were
used as a positive control. After 16h of treatment, floating and
attached cells were collected, washed twice with PBS, and
incubated at 41C with antibodies against DR4, DR5, DcR1, and
DcR2, followed by a secondary FITC-conjugated IgG, and the cells
analysed by flow cytometry. Cytoplasmic expression of TRAIL
receptors was assessed after cell permeabilisation. Briefly, cells
were fixed in 4% formaldehyde in PBS for 30min, washed,
permeabilised with a saponine solution (0.02% saponine in PBS
plus 1% FCS) for 30min, incubated with the antibodies as
described above, and assessed by flow cytometry.
RT–PCR analysis
Total RNA was isolated from 10
6 MM and Met-5A cells before and
after treatment with 30mM a-TOS, using Trizol (Life Technologies,
Rockville, MD, USA), according to the manufacturer’s protocol.
The first-strand cDNA was synthesised using the GeneAmp RNA
PCR kit (PerkinElmer Life Sciences, Boston, MA, USA). PCR
analyses were performed in the final volume of 20ml of buffer
containing 1ml of the retro-transcription product, all four dNTPs
(150mM each), MgCl2 (2mM), 1U of Taq Gold polymerase (Roche
Molecular Biochemicals, Basel, Switzerland), and each primer at
1mM. The house-keeping gene b-actin was used as a loading
control. The sequences of primers were as published elsewhere
(Bernard et al, 2001).
Immunocytochemistry
The MM cells were placed overnight in 35-mm dishes on poly-L-
lysine-coated glass coverslip. After 4h of incubation with a-TOS
(30mM) or hrTRAIL (50ngml
 1) separately or in combination, the
cells were washed two times with PBS, fixed with freshly prepared
3% formaldehyde in PBS, and incubated with saponine solution
(0.05% saponine and 2% FCS in PBS). Cells were then incubated
with mouse antihuman cytochrome c IgG in saponine solution for
1h at room temperature. FITC-conjugated, antimouse secondary
IgG was added. The coverslips were mounted on glass slides with
Vectashield (Vector Laboratories, Inc., Burlingame, CA 94010,
USA) and viewed in a fluorescence microscope.
Confocal microscope analysis
Met-5A and MM-B1 cells were plated in a six-well plate at 2 10
5
and transiently transfected with pDsRed1-N1 harbouring RFP, and
with GFP-expressing vector (pGFP) (BD Biosciences, Palo Alto,
CA, USA), respectively. The transfection was carried out by using
the GenePorter transfection reagent (Gene Therapy Systems, Inc.,
San Diego, CA, USA) following the manufacturer’s instructions.
Briefly, cells were incubated with 1ml of the serum-free medium
DNA/GenePorter transfection reagent complex, which was pre-
pared by mixing 2mg DNA with 0.5ml serum-free medium, and
this was combined with 10ml of GenePorter transfection reagent
mixed with 0.5ml serum-free medium, followed by 30min
incubation at room temperature. After 3h of incubation with the
transfection complex, cells were washed and cultured for 48h. The
Met-5A-RFP and MM-B1-GFP cells were mixed and adhered on
poly-L-lysine-coated glass coverslips. The transfected Met-5A-RFP
and MM-B1-GFP cells were treated for 12h with hrTRAIL and a-
TOS at 50ngml
 1 and 30mM, respectively. The cells were washed
two times with PBS, fixed with freshly prepared 3% formaldehyde
in PBS, and the coverslip was mounted with Vectashield plus DAPI
(Vector Laboratories, Burlingame, CA 94010, USA) and viewed in a
confocal microscope (BioRad, MRC 1024, Hercules, CA, USA).
Statistical analysis
All experiments were conducted at least three times, and data are
shown as mean7s.d. Significance was evaluated by the ANOVA
repeated measure test. Data were considered statistically signifi-
cant at Po0.05.
RESULTS
a-Tocopheryl succinate and TRAIL exert different toxicity
towards MM and nonmalignant mesothelial cells
Treatment of MM and nonmalignant mesothelial cell lines with a-
TOS results in dose-dependent cytotoxicity. Figure 1A shows
viability curves of MM-B1, Meso-2, and Ist-Mes cell lines with IC50
values ranging from 34 to 38mM of a-TOS (Table 1). The cells were
relatively resistant to TRAIL-induced cell death; the viability curve
reached a plateau at 0.5mgml
 1, and, except for the MM-B1 cells
with 40–50% of dead cells, MM cells did not exert more than
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Figure 1 Cytotoxic effect of a-TOS and hrTRAIL in MM and mesothelial
cell lines. Cells were seeded into 96-well tissue culture plates (2.5 10
3 per
well) and treated with increasing concentrations of a-TOS (A) and
hrTRAIL (B). Survival curves for MM-B1, Meso-2, Ist-Mes, and Met-5A cell
lines are based on the results of MTT assays after 24h of drug exposure. All
data are expressed as mean7s.d. from three independent experiments.
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s10–15% cell death at pharmacologically relevant doses of TRAIL
(Figure 1B, Table 1). Importantly, nonmalignant mesothelial cells
(Met-5A) exhibited minimal toxicity in the presence of a-TOS as
well as hrTRAIL at concentrations of up to 80 and 10mgml
 1,
respectively (Figure 1A and B).
a-Tocopheryl succinate and TRAIL show synergistic effect
towards MM but antagonise each other in nonmalignant
mesothelial cells
To investigate the effect of a-TOS on TRAIL-induced cytoxicity,
MM cells were exposed to increasing concentrations of individual
drugs alone and in combination, cell viability was assessed
and isobologram analysis performed. Isobolograms were created
at the IC50 values as described elsewhere (Tsai et al, 1989). The IC50
unit values for a-TOS o1 were plotted against corresponding
IC50 unit values for hrTRAIL; the distribution of points along
the diagonal connecting the values of 1 suggests an additive effect
of the two drugs while the points below or above the line indicate
their synergism and antagonism, respectively (Figure 2). Thus,
the effects of a-TOS and hrTRAIL on cell death induction
were synergistic in MM-B1 and Meso-2 cells and, to a lesser
extent, in Ist-Mes cells where a synergistic/additive effect
was observed. Notably, an antagonistic effect was found when
the two drugs were combined in nonmalignant mesothelial cells,
in which most of the points lie above the diagonal. Table 1 shows
that the high IC50 values for TRAIL decreased by a factor of B10–
100 when a-TOS was present at subapoptotic levels in the case
of MM cells, while no effect was observed for Met-5A cells. Finally,
a-TOS enhanced TRAIL-induced apoptosis of MM cells in a
dose- and time-dependent manner, while only marginal and
nonsignificant apoptosis was observed in the nonmalignant
mesothelial cells (Figure 3). We next attempted to directly show
the selectivity of MM cells for synergistic effect of TRAIL and a-
TOS. For this, we transfected the Met-5A cells with a plasmid
harbouring RFP, while MM-B1 cells with a GFP. The cells were
then combined in culture and exposed to hrTRAIL plus a-TOS.
Figure 4 reveals that the combination of the two agents selectively
induced apoptosis MM cells without affecting the nonmalignant
mesothelial cells, since the DAPI-visualised nuclei were condensed
in the ‘green’ malignant cells, whereas no nuclear morphological
changes were observed in the ‘red’ nonmalignant cells (6478 vs
1074% of apoptotic cells for MM-B1 and Met-5A, respectively).
These observations directly document the intriguing paradigm
of selective sensitisation of MM cells to TRAIL-dependent killing
by a-TOS.
a-Tocopheryl succinate differentially modulates expression
of TRAIL receptors
To explore the possibility that a-TOS modulates TRAIL cytotoxi-
city by regulating expression of its receptors, we analysed the
extent of TRAIL death and DcR expression at both mRNA and
protein level. RT–PCR analysis shows that the expression of the
DR4 and, in particular, DR5 mRNA was enhanced in MM cells
treated with subapoptotic (30mM) a-TOS (Figure 5A). On the other
hand, the level of the expression of the DcR1 and DcR2 mRNA
remained unchanged (data not shown). a-TOS failed to modulate
the level of expression of both death and DcR mRNA in Met-5A
cells (Figure 5B). Time course analysis shows that exposure of MM
cells to a-TOS upregulated DR5 in a time-dependent manner, with
a two-fold increase in DR5 mRNA at 4h (Figure 5C), that is, at
least 4h before the detection of first signs of apoptosis (cf
Figure 3B). Flow cytometric analysis, performed on both
nonpermeabilised and permeabilised cells revealed that MM cells
express both DR4 and DR5 protein on cell surface and in the
cytoplasm (Figure 6A). DcR1 was not expressed in any of the cell
lines tested, whereas DcR2 was detected only in the cytoplasmic
compartment (Figure 6A). Sublethal doses of a-TOS increased the
expression of the DR4 and, more so, DR5 protein without affecting
expression of the DcR1 and DcR2 protein (Figure 6A). The basal
level of the DR4 and DR5 protein was lower in Met-5A cells then in
Table 1 IC50 values and killing efficacy of a-TOS, hrTRAIL, and hrTRAIL plus a-TOS in malignant mesothelioma and nonmalignant mesothelial cell lines
a-TOS hrTRAIL hrTRAILa-TOS
Cell type IC50 (lM) Max effect (% cell death) IC50 (lgml
 1) Max effect (% cell death) IC50 (lgml
 1) Max effect (% cell death)
MM-B1 36749 6 73 0.370.1 6474 0.01070.002 8779
Meso-2 38779 5 75 5.071.0 5572 0.03070.004 7677
Ist-Mes 35769 6 74 0.770.1 3275 0.10070.050 69710
Met-5A 55784 4 72 0.570.1 2673 0.45070.150 3478
The IC50 values for a-TOS, hrTRAIL, and hrTRAIL (50ngml
 1) plus a-TOS (30mM) were calculated from dose–response curves of MM and nonmalignant mesothelial cells at
24h of treatment. Data are expressed as mean7s.d. from three independent experiments.
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Figure 2 hrTRAIL and a-TOS combination exhibit synergistic effects in
MM cells and antagonise each other in nonmalignant mesothelial cells. The
synergist/antagonistic effect of hrTRAIL and a-TOS was evaluated by
isobolograms at IC50 based on the results of MTT assays for MM-B1 (A),
Meso-2 (B), Ist-Mes (C), and Met-5A cells (D) treated with combinations
of the two drugs. Each diagram combines the results at least of three
independent experiments.
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stheir malignant counterparts, whereas no expression of the DcR1
and DcR2 protein was detected in Met-5A cells (Table 2). Finally,
Met-5A cells exposed to a-TOS showed only a nonsignificant
increase of the DR expression (Figure 6B, Table 2).
a-Tocopheryl succinate facilitates the TRAIL proapoptotic
signalling
TRAIL-induced apoptosis can be characterised by activation of
caspases, including caspase-8, -9, and -3, with their pattern of
activation being cell type-dependent (Griffith et al, 1998). When
MM cells were treated with TRAIL, caspase-8 was transiently
activated, as shown by increased protease activity at 4h and by the
procaspase cleavage as soon as at 1h of incubation (Figure 7A and
B). This activation of caspase-8 at 4h was correlated with only low
levels of apoptosis (cf Figure 3B and C). Combined treatment with
TRAIL and a-TOS, which overcame resistance of MM cells to
TRAIL, resulted in very low level of caspase-8 activity, but
promoted caspase-9 activation (Figure 7A and B).
The link between caspase-8 and -9 activation may be mediated
by the proapoptotic cleavage of Bid. Indeed, combination of a-TOS
and TRAIL resulted in early (1-h) Bid cleavage, triggering the
ensuing proapoptotic mitochondrial events, including the cytosolic
mobilisation of cytochrome c (Figure 8A and B). Preincubation
with the caspase-8 inhibitor Z-IETD-FMK inhibited the synergistic
effect of TRAIL and a-TOS but not a-TOS-induced apoptosis, while
treatment with the pan-caspase inhibitor, Z-VAD-FMK, completely
inhibited apoptosis in MM cells, regardless of the treatment
regimen (Figure 9A and B).
DISCUSSION
The aim of the study was to investigate the effect of combined
treatment of MM cells with a-TOS and TRAIL. As a-TOS exerts its
Figure 3 Effect of hrTRAIL, a-TOS alone or their combination on
apoptosis induction in MM cells. (A) MM-B1 and Met-5A cells were
exposed to increasing concentrations of hrTRAIL alone (50ngml
 1)o ri n
combination with a sublethal dose of a-TOS (30mM) and their viability was
assessed at 24h. (B) MM-B1 cells were exposed to hrTRAIL (50ngml
 1)
or a-TOS (30mM) alone or in combination at the indicated time points, and
apoptosis was evaluated by annexin-V-FITC. (C) Mesothelioma (MM-B1,
Meso-2, Ist-Mes) and mesothelial (Met-5A) cells were treated for 24h with
50ngml
 1 hrTRAIL, 30mM a-TOS, or 50ngml
 1 hrTRAIL plus 30mM a-
TOS and evaluated for apoptosis. * The combined effect was significantly
greater than the effects of individual agents, Po0.05. Results are expressed
as mean7s.d. from three independent experiments.
Control Control hrTRAIL+    -TOS
Met-5A-RFP
Met-5A-RFP
MM-B1-GFP
MM-B1-GFP
Met-5A-RFP
MM-B1-GFP
Met-5A-RFP
MM-B1-GFP
Figure 4 hrTRAIL and a-TOS combination selectively induce apoptosis in MM cells. Met-5A and MM-B1 were transiently transfected with pDsRed1-N1
and pGFP, respectively. The transfected cells were combined and allowed to adhere to coverslips, and were treated for 12h with hrTRAIL and a-TOS at
50ngml
 1 and 30mM, respectively. The coverslips were then mounted in Vectashield plus DAPI and viewed in a confocal microscope. The hrTRAIL/a-TOS
treatment induced nuclear condensation in the ‘green’ MM-B1-GFP cells (arrows), whereas no such nuclear morphological changes were observed in the
‘red’ Met-5A-RFP cells.
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sproapoptotic activity via the distal, mitochondrial route, and
TRAIL-induced cell death is relayed via the proximal pathway,
triggered by the cell surface receptor engagement, we hypothesised
that the two different modes of action could potentiate apoptosis
in the TRAIL-resistant MM cells. If so, TRAIL and the vitamin E
analogue could represent interesting drugs for combinatorial
treatment of MM, a thus far incurable neoplastic disease.
Our results herein clearly demonstrate a cross-talk between a-
TOS and TRAIL in several processes resulting in efficient apoptosis
induction in MM cells. Thus, in all MM cell lines tested, a-TOS was
found to enhance TRAIL-induced cell death in a synergistic
manner regardless of their phenotype (cf Figure 2 and 3), while
MM cells exerted relative resistance to TRAIL alone at as much as
10mgml
 1 of the agent. Important too, a-TOS and TRAIL exerted
an antagonistic effect in case of nonmalignant mesothelial cells
(cf Figure 2). This is a highly intriguing finding, since it points to
the possibility that, if applied together, a-TOS and TRAIL will
efficiently and selectively kill MM cells while protecting the
neighbouring nonmalignant mesothelial cells of the pleural or
peritoneal cavity (cf Figure 4). This notion is consistent with
reports showing protective activity of a-TOS towards normal cells
and tissues (Vuchetich et al, 1996; Zhang et al, 2001). The reason
for this protective effect is, most likely, due to conversion of a-TOS
to a-tocopherol (a-TOH), as shown, for example, for hepatocytes
(Fariss et al, 2001). This is consistent with the notion that a-TOS
has a dual activity: as a-TOS, the provitamin form, it causes
apoptosis in malignant cells, thereby suppressing tumour growth,
while as a-TOH, the vitamin form, it acts as an antioxidant
protecting normal cells from insults such as inflammation (Neuzil,
2002).
The biphasic viability curve for MM cells treated with TRAIL
(cf Figure 1B) indicates either the presence of two different cell
populations, resistant and sensitive, or the development of
resistance during treatment. Indeed, MM cells pretreated with
TRAIL developed resistance against a second TRAIL exposure,
reaching a maximum at 8h and decaying after 24h of incubation
(Tomasetti et al, unpublished data), suggesting an intrinsic
mechanisms of the cells for evading apoptosis. The presence of
this resistant subpopulation may be due to initial activation of
survival pathways (Ehrhardt et al, 2003), and a-TOS may sensitise
the resistant cells by interfering with these pathways (Neuzil,
2002).
A cooperative proapoptotic effect of a-TOS with immunological
apoptogens has been observed in breast cancer (Yu et al, 1999) and
colon cells (Weber et al, 2002). The former report showed that a-
TOS converted the Fas-resistant to Fas-sensitive cells via
mobilisation of the Fas receptor from the cytosol to the plasma
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Figure 5 Effect of a-TOS treatment on the expression of TRAIL
receptors in MM and mesothelial cells. The death receptors (DR4, DR5)
were evaluated in MM-B1 (A) and Met-5A cells (B) as mRNA expression
before and after treatment with 30mM a-TOS for 4h. (C) MM-B1 cells
were treated with 30mM a-TOS at the indicated time points, and mRNA
expression of DR5 evaluated. Results in panels (A)–(C) are representative
of three independent experiments.
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Figure 6 Cell surface expression of TRAIL receptors evaluated on
permeabilised and nonpermeabilised MM and mesothelial cells after a-TOS
treatment. TRAIL receptor protein analysis was performed on MM-B1 (A)
and Met-5A (B) cells. Cells were seeded at 3 10
5 per well into six-well
plates and exposed to a-TOS for 16h. Permeabilised and nonpermeabi-
lised cells were then incubated with antibodies against DR4, DR5, DcR1, or
DcR2, and their expression was evaluated by flow cytometry. Results are
representative of three independent experiments with similar results.
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smembrane. Thus, enhancement of DR expression on cell surface
could enhance cancer surveillance. We show here that higher
expression of TRAIL DRs, in particular DR5, by a-TOS on the
surface of MM cells was due to de novo synthesis rather than
translocation of TRAIL receptors from cytoplasm to the plasma
membrane (cf Figure 6). It has been reported previously that cells
can be sensitised to TRAIL by upregulation of DR5 in response to
activation of the transcription factor p53, suggesting that enhanced
DR5 expression may be a common mechanism for apoptosis
induction by DNA-damaging agents (Wu et al, 1997). We have
recently observed that exposure of cancer cells to a-TOS results in
early generation of reactive oxygen species (ROS) (Weber et al,
2003), and we have also observed phosphorylation of p53
(Tomasetti et al, unpublished data). It is thus feasible that a p53-
mediated process contributes to a-TOS-induced DR5 upregulation
in MM cells, consistent with another report suggesting p53
activation as a mode of sensitisation of cancer cells towards
TRAIL killing (Xie et al, 2001). Although Met-5A cells, used here as
a control cell line, are immortalised with SV-40 resulting in
inactivation of p53, translocation of p53 into the nucleus was also
observed in these cells following a-TOS treatment (unpublished
data). However, p53 activation results in a small increase of DRs
expression in Met-5A, contrary to that observed in MM cell lines.
Since we have also found that exposure of cells to a-TOS leads to
very fast activation of sphingomyelinase resulting in early
accumulation of ceramide (Weber et al, 2003), which has
been suggested to upregulate DRs (Herr et al, 1999), additional/
alternative mechanisms cannot be ruled out, including modulation
of expression of bcl-2 family proteins (Ray and Almasan, 2003).
However, we observed that upregulation of DRs is not followed
by an increase of caspase-8 activity suggesting that other
mechanisms are involved in the synergistic a-TOS/TRAIL MM
cell killing.
Kinetics analysis of TRAIL-induced signalling revealed a
transient activation of caspase-8, which resulted in induction,
albeit low, of apoptosis. Caspase-8 activation was less pronounced
in the presence of TRAIL plus a-TOS. Under this setting, we
observed activation of the mitochondria-dependent apoptotic
pathway, including Bid cleavage, cytochrome c cytosolic mobilisa-
tion and, finally, caspase-9 activation. Bid cleavage may lead to
mitochondrial translocation of Bax, as shown for a-TOS in other
cancer models (Weber et al, 2003; Yu et al, 2003). Preincubation of
MM cells with the caspase-8 inhibitor Z-IETD-FMK inhibited the
synergistic effect of TRAIL and a-TOS, while treatment with the
pan-caspase inhibitor Z-VAD-FMK completely inhibited apoptosis
initiated by the two inducers alone or in combination. These
results clearly document that caspase-8 activation is essential for
the TRAIL-dependent effect, and that this is significantly amplified
by activation of caspase-9 in the presence of subapoptotic levels of
a-TOS. Thus, there is a cross-talk between a-TOS and TRAIL in
potentiation of apoptotis in the TRAIL-resistant MM cells, in
particular in linking the receptor- and mitochondria-associated
events.
Table 2 Evaluation of cell surface expression of TRAIL receptors before and after a-TOS treatment in MM and mesothelial cells
DR4 DR5 DcR1 DcR2
Cell type Ctrl a-TOS Ctrl a-TOS Ctrl a-TOS Ctrl a-TOS
MM-B1 2.570.30 3.170.25 4.370.50 5.970.72 1.270.20 1.270.21 1.070.11 1.070.14
Meso-2 1.670.25 2.470.32 2.070.12 6.770.52 1.170.21 1.170.35 1.070.10 1.070.12
Ist-Mes 1.770.54 2.070.38 3.670.61 4.370.52 1.370.20 1.170.22 1.070.11 1.070.09
Met-5A 1.970.31 2.270.41 1.770.46 1.870.33 1.070.05 1.070.06 1.070.14 1.270.08
The expression of TRAIL receptors was evaluated by flow cytometry before (Ctrl) and after treatment with a-TOS (30mM, 16h) in MM and mesothelial cells. The values
represent the fluorescence intensity of the receptors normalised for a blank incubated with an irrelevant primary antibody. Data are expressed as mean7s.d. from three
independent experiments and statistical differences between controls vs a-TOS treatment are bold, Po0.005.
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Figure 7 Activation of caspase-8 and -9 by hrTRAIL and a-TOS alone or
by their combination in MM cells. MM-B1 cells were treated with
50ngml
 1 hrTRAIL, 30mM a-TOS, or 50ngml
 1 hrTRAIL plus 30mM a-
TOS, the activity of caspase-8 and -9, expressed as OD/min per mg protein
(A), or caspase-8 and -9 cleavage (B), were assessed at the indicated time
points. Data are expressed as mean7s.d. from three independent
experiments.
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Figure 8 Drug combination determines Bid cleavage and cytochrome c
release. MM-B1 cells were treated with 50ngml
 1 hrTRAIL, 30mM a-TOS,
or 50ngml
 1 hrTRAIL plus 30mM a-TOS, Bid cleavage (A) and
cytochrome c released from mitochondria (B) were assessed. Picture
shown is representative for at least two independent experiments.
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sOur data suggest that cleavage of Bid may be considered as the
link between the proximal and distal apoptotic signalling path-
ways. A similar scenario for a cross-talk between the two routes
has been suggested by others. Thus, cleavage of Bid is involved in
sensitisation to TRAIL of colorectal (Lacour et al, 2001; Ravi and
Bedi, 2002) and prostate cancer cells (Nimmanapalli et al, 2001).
These reports show an increased activity of caspase-8 associated
with the sensitisation, suggesting the type II cells, that is, cells
where receptor-mediated proapoptotic signalling is transmitted
downstream via Bid cleavage following the death-inducing
signalling complex (DISC) formation on the cytosolic terminus
of the DRs (Ashkenazi and Dixit, 1998). However, our observations
with MM cells point to Bid cleavage at minimal caspase-8
activation in the presence of TRAIL and a-TOS, while TRAIL
alone, causing higher activation of caspase-8, is inefficient in
apoptosis induction and Bid cleavage does not occur. Therefore,
there appears to be a block in the type I signalling in MM cells
downstream from caspase-8 to the effector caspases, and a cross-
talk between a-TOS and TRAIL, causing Bid cleavage resulting in
mitochondrial signalling that then culminates in efficient apopto-
sis. Thus, MM cells, from the point of view of apoptotic signalling,
may represent atypical type II cells (Scaffidi et al, 1998), possibly
consistent with their general resistance to apoptosis, causing
mesotheliomas incurable.
Taken together, we report that sublethal doses of a-TOS
selectively enhance TRAIL-dependent apoptotic signalling in MM
via mitochondrial pathways, while antagonising the activity of
TRAIL in nonmalignant mesothelial cells. The observed sensitisa-
tion of MM cells to TRAIL killing is associated with increased
expression of DR4 and DR5, and with activation of the
mitochondrial proapoptotic signalling with Bid cleavage linking
the proximal and distal events, although the precise contribution
of the parallel/auxiliary pathways to the overall efficacy of
apoptosis execution in MM cells is not known at present. The
importance of activation of both types of signalling in sensitisation
of cancer cells to TRAIL has been recently shown for prostate
cancer cells (Ray and Almasan, 2003). Our findings are in accord to
those of Liu et al, 2001, reporting that sensitisation of MM cells
toward TRAIL by chemotherapeutic is dependent on the
mitochondrial pathway, in a c-Jun N-terminal kinase (JNK)-
dependent manner (Vivo et al, 2003). Thus, a-TOS, although also
acting via the JNK pathway (Yu et al, 2001) signalling downstream
through Bax (Lei et al, 2002), promotes the receptor-dependent
pathway, thereby maximizing the apoptotic potential of the cell. In
conclusion, our data show that a-TOS efficiently potentiates TRAIL
killing of MM cells that are highly resistant to established
treatment via mitochondrial mechanisms, and prompt testing of
TRAIL and a-TOS, as well as other vitamin E analogues (Birringer
et al, 2003), in preclinical models of MM. The potential
combinatorial clinical use of a-TOS and TRAIL is supported by
our recent findings that the vitamin E analogue promotes survival
of immunocompromised mice with experimental peritoneal
mesothelioma (Tomasetti et al, in press).
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